Steven Cohen's ACAD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 3.38 M shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $90.21 M, representing 0.10% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in ACAD, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2024, adding 2.93 M shares. Largest reduction occurred in Q3 2024, reducing 3.71 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.89 M | Add 127.22% | 3.38 M | $26.71 |
| Q3 2025 | -1.69 M | Reduce 53.15% | 1.49 M | $21.34 |
| Q2 2025 | -1.48 M | Reduce 31.74% | 3.17 M | $21.57 |
| Q1 2025 | +2.42 M | Add 108.35% | 4.65 M | $16.61 |
| Q4 2024 | +2.23 M | New Buy | 2.23 M | $18.35 |
| Q3 2024 | -3.71 M | Sold Out | 0 | $0.00 |
| Q2 2024 | +2.93 M | Add 377.68% | 3.71 M | $16.25 |
| Q1 2024 | +383,873 | Add 97.72% | 776,700 | $18.49 |
| Q4 2023 | +342,184 | Add 675.68% | 392,827 | $31.31 |
| Q3 2023 | -841,283 | Reduce 94.32% | 50,643 | $20.84 |
| Q2 2023 | +232,420 | Add 35.24% | 891,926 | $23.95 |
| Q1 2023 | -456,394 | Reduce 40.90% | 659,506 | $18.82 |
| Q4 2022 | +1.12 M | New Buy | 1.12 M | $15.92 |
| Q1 2021 | -167,100 | Sold Out | 0 | $0.00 |
| Q4 2020 | -411,095 | Reduce 71.10% | 167,100 | $53.46 |
| Q3 2020 | +379,685 | Add 191.27% | 578,195 | $41.25 |
| Q2 2020 | +198,510 | New Buy | 198,510 | $48.47 |
| Q1 2020 | -671,009 | Sold Out | 0 | $0.00 |
| Q4 2019 | +671,009 | New Buy | 671,009 | $42.78 |
| Q3 2019 | -1,600 | Sold Out | 0 | $0.00 |
| Q2 2019 | -389,928 | Reduce 99.59% | 1,600 | $26.88 |
| Q1 2019 | -1.86 M | Reduce 82.57% | 391,528 | $26.85 |
| Q4 2018 | +439,600 | Add 24.33% | 2.25 M | $16.17 |
| Q3 2018 | -1.29 M | Reduce 41.61% | 1.81 M | $20.76 |
| Q2 2018 | -1.26 M | Reduce 28.98% | 3.09 M | $15.27 |
| Q1 2018 | +1.96 M | Add 81.86% | 4.36 M | $22.47 |
| Q4 2017 | +1.67 M | Add 230.41% | 2.4 M | $30.11 |
| Q3 2017 | -680,822 | Reduce 48.42% | 725,200 | $37.67 |
| Q2 2017 | -525,178 | Reduce 27.19% | 1.41 M | $27.89 |
| Q1 2017 | +706,200 | Add 57.65% | 1.93 M | $34.38 |
| Q4 2016 | -846,500 | Reduce 40.86% | 1.22 M | $28.84 |
| Q3 2016 | +871,800 | Add 72.67% | 2.07 M | $31.81 |
| Q2 2016 | -1.02 M | Reduce 46.03% | 1.2 M | $32.46 |
| Q1 2016 | +1.92 M | Add 631.63% | 2.22 M | $27.96 |
| Q4 2015 | -1.71 M | Reduce 84.90% | 303,800 | $35.65 |
| Q3 2015 | +664,744 | Add 49.34% | 2.01 M | $33.07 |
| Q2 2015 | -900,044 | Reduce 40.05% | 1.35 M | $41.88 |
| Q1 2015 | +1.23 M | Add 120.63% | 2.25 M | $32.59 |
| Q4 2014 | +93,600 | Add 10.12% | 1.02 M | $31.75 |
| Q3 2014 | -157,000 | Reduce 14.51% | 925,000 | $24.76 |
| Q2 2014 | +1.08 M | Add 0.00% | 1.08 M | $22.59 |
Steven Cohen's ACADIA Pharmaceuticals Investment FAQs
Steven Cohen first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q2 2014, acquiring 1,082,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held ACADIA Pharmaceuticals Inc. (ACAD) for 41 quarters since Q2 2014.
Steven Cohen's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q2 2024, adding 3,710,140 shares worth $60.29 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 3,377,311 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $90.21 M.
As of the Q4 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.10% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 4,647,816 shares, as reported at the end of Q1 2025.